摘要
目的观察埃索美拉唑三联疗法对幽门螺杆菌(Hp)阳性的消化性溃疡的临床疗效。方法将符合条件的90例患者随机分为A、B两组,A组45例,应用埃索美拉唑20 mg+阿莫西林1 g+克拉霉素500 mg,每日2次,共7 d;B组45例,应用奥美拉唑20 mg+阿莫西林1 g+克拉霉素500 mg,每日2次,共7 d;治疗1周后,A组和B组分别继续单服埃索美拉唑20mg或奥美拉唑20 mg每日1次继续治疗3周。治疗前、治疗4周后均进行胃镜和Hp检查,评估疗效。结果埃索美拉唑组与奥美拉唑溃疡愈合率分别为95.56%和93.33%,两组间差异无统计学意义(P>0.05);幽门螺杆菌清除率分别为91.11%和75.56%,两组间差异有统计学意义(P<0.05)。结论埃索美拉唑三联可作为幽门螺杆菌感染的消化性溃疡的一线疗法。
Objective To evaluate the clinical efficacy of triple therapies of esomeprazole for the treatment of peptic ulcer with helicobacter pylori （Hp） infection. Methods A total of 90 patients consistent with selected condition were randomly divided into group A （45 cases, 20 mg of esomeprazole ＋ 1 000 mg of amoxicillin ＋ 500 mg of clarithromycin, twice daily） and group B （45 cases, 20 mg of omeprazole ＋ 1 000 mg of amoxicillin ＋ 500 mg of clarithromycin, twice daily）. After 1-week treatment, group A and group B continuously took oral esomeprazole 20 mg and omeprazole 20 mg alone, once daily. After continuous 4-week treatment, gastroscopy was performed again and Hp were redetected and analyzed. Results The ulcer healing rates in the group A and B were 95.56% and 93.33% respectively, showing no significant difference （P 〉0.05）. The Hp eradication rates were 91.11% and 75.56% respectively, showing significant difference （P 〈0.05）. Conclusions Esomeprazole-based triple therapy may be the first line of therapy for treating peptic ulcer with Hp infection.
出处
《临床医学工程》
2014年第9期1145-1146,共2页
Clinical Medicine & Engineering
